|
Doing well and doing good
|
|
|
Biotech Receptos Holds Successful IPO
Polaris achieved records for successful exits and funds distributed to Limited Partners in 2012. This year starts with the IPO of biotech Receptos, which will use the proceeds to support the advancement of therapies for the treatment of immune and metabolic diseases. That's what we call doing well and doing good. See Story
|
|
Community is our strength
|
Firm Starts Three New Cos. in Q2 by Repeat (Polaris) Entrepreneurs When we say community is our strength, we mean it. Polaris recently made investments in U.S. HealthVest ($36 million financing); AgBiome ($14.5 million financing); and Avitide--all founded by repeat Polaris entrepreneurs. Tim Kilgallon, the former CEO of Polaris-backed Free & Clear, also joined the firm as CEO-in-Residence. See Story
|
|
Polaris Puts $60 Million to Work. In the first five months of 2013, Polaris made six new investments and financed 22 follow-on rounds across a range of Technology, Healthcare and Consumer companies. Among the new investments is the exciting seed stage technology company Bluetrain Mobile, which offers tools for building more-engaging mobile websites. See Story
|
|
An honor for one of our own
|
Midas List: Top Life Sciences Investors of 2013 Four Polaris healthcare companies were acquired in 2012 at a gross transaction amount of nearly $2 billion. Included in these deals was the $415 million acquisition of deCODE Genetics by Amgen. This investment and others landed Polaris' Terry McGuire on Forbes' annual Midas list of top life sciences investors. See Story
|
|
|
|
Cardlytics Demonstrates Truly Targeted Advertising; Goes After $380 Billion Yearly U.S. Ad Spend The promise of truly targeted advertising has always seemed to be just around another corner. Until now. "We can reach very active shoppers with ads they actually want to see, and distribute them online and via mobile to an audience that approaches Facebook levels," says Cardlytics CEO Scott Grimes. See Story
|
Ocular Therapeutix Looks to Bring Novel Products to the Billion Dollar Eye Care Market At innovative eye-care company Ocular Therapeutix, the company awaits perhaps its most important milestone, namely FDA approval of its first product--a potential new standard of care therapy to seal incisions following eye surgery. See Story
|
|
